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The benefits of cardiac imaging are immense, and modern medicine requires the extensive and versatile use of a variety of cardiac imaging tech-
niques. Cardiologists are responsible for a large part of the radiation exposures every person gets per year from all medical sources. Therefore,
they have a particular responsibility to avoid unjustified and non-optimized use of radiation, but sometimes are imperfectly aware of the radio-
logical dose of the examination they prescribe or practice. This position paper aims to summarize the current knowledge on radiation effective
doses (and risks) related to cardiac imaging procedures. We have reviewed the literature on radiation doses, which can range from the equivalent
of 1–60 milliSievert (mSv) around a reference dose average of 15 mSv (corresponding to 750 chest X-rays) for a percutaneous coronary inter-
vention, a cardiac radiofrequency ablation, a multidetector coronary angiography, or a myocardial perfusion imaging scintigraphy. We provide a
European perspective on the best way to play an active role in implementing into clinical practice the key principle of radiation protection that:
‘each patient should get the right imaging exam, at the right time, with the right radiation dose’.
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Introduction
Medical radiation from X-rays and nuclear medicine is the largest
man-made source of radiation exposure in Western countries, and
accounts for a mean effective dose (ED) of 3.0 milliSievert (mSv)
per person per year, equivalent to the radiation dose of 150 chest
X-rays (CXR).1 The natural background radiation worldwide is
about 2.4 mSv 2 (Figure 1). Cardiologists are responsible for about
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40% of the entire cumulative ED to the US population from all
medical sources excluding radiotherapy.3 In addition, the occupa-
tional radiation exposure of interventional cardiologists and cardiac
electrophysiologists can be two to three times higher than that of
diagnostic radiologists,4 and their exposure has increased steadily
in the past few decades.5
The increasing use and complexity of imaging and interventional
techniques have not been matched by increasing awareness and
knowledge by prescribers and practitioners. The majority of
doctors—including cardiologists—grossly underestimate the radi-
ation doses for most commonly requested tests.6,7 The significant
increase in the cumulative exposure of patients and population to
ionizing radiation is likely to cause an increased incidence of cancer
in years down the line, with an important yet potentially avoidable
public health threat.8 Cancer induction associated with radiation
goes unrecognized because it is neither differentiable nor predictable
for individual patients, and because clinically significant consequences
do not become evident for many years. The balance between
risks and benefits determines the appropriateness score of a test:
the test is appropriate when benefit greatly exceeds the risks, and
inappropriate when risk exceeds the benefit.9 According to recent
estimates, at least one-third of all cardiac examinations are partially
or totally inappropriate,10 i.e. risks and costs outweigh benefits.
The risk–benefit assessment is a ‘dynamic’, tailored variable rather
than an absolute, fixed concept, since the same test can have a favour-
able risk–benefit ratio in an individual with intermediate pre-test
probability and equivocal ECG, and totally inappropriate in a
middle-aged woman with atypical chest pain and maximal negative
ECG stress test. The order of magnitude of the risks of several
imaging techniques (or associated procedures, such as stress or con-
trast administration) may range between 1–10% (contrast-induced
nephropathy) and 0.1–0.3% (severe reaction during stress adminis-
tration of dobutamine or dipyridamole). Therefore, radiation risks
are certainly not the only, and probably also not the most important
of the risks to be included in the risk-side of our risk–benefit assess-
ment. However, they are probably the least well known and the least
considered in our daily decision making.11
Biological effects of radiation
There are two main biological effects of radiation (Table 1): tissue
reactions (deterministic effects), which happen when the radiation
dose exceeds a specific threshold and become evident days to
months after exposure as they cause a predictable change in
tissue,12 and stochastic effects, which relate to the potential for
future harm to the tissue and the body. Tissue reactions of most
Figure 1 Medical and natural sources of radiation per person per year. Modified from Picano1 and updated from Mettler et al.2
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Dose level Medium to high Low
Latency period Short (days or weeks) Long (years)
Threshold
dose




Predominantly cell death Cell damage
Sample clinical
effects
Skin lesions; cataract Cancer, inherited defect
in offspring
E. Picano et al.666







concern for patients and operators include skin injuries (reported in
patients undergoing long, repeated and complicated interventional
procedures13) and cataract (present in one-third to half of interven-
tional cardiologists or radiologists14). The stochastic effect of most
concern is a carcinogenic effect. It occurs when the cell is modified
by damage to its DNA but remains viable, the harm eventually
being expressed through cell proliferation.15 Ionizing radiation
damages DNA molecule either directly (through ionization of
DNA molecule) or indirectly (through generation of free radicals
and reactive oxygen species in the surrounding medium). Cancer
may occur after a latency period of many years. The reduction of
risk of cancer is at the core of the radiation protection system for
patients and staff.16 The available epidemiological evidence linking
increased cancer risk to radiation exposure is now strong for doses
.50 mSv,17,18 also for diagnostic medical exposures.19 In contem-
porary imaging practice, doses .50–100 mSv are sometimes
reached after cumulative exposures20 in a single hospital admission21
and not infrequently by a patient in multiple examinations and diag-
nostic or interventional procedures for a single imaging technique22
and even in a single examination.23 For any given radiation exposure,
the cancer risk is higher in females than in males, in children than in
adults, and in adults than in elderly, and may differ among individuals
(Figure 2). From a radiation sensitivity standpoint, not all tissues
have the same risk of radiation-induced cancer (Table 2). The
radiation-induced cancer is clinically undistinguishable from a spon-
taneously occurring cancer. Out of 100 subjects exposed to
100 mSv (roughly equivalent to 5000 CXRs), 42 will develop a
spontaneous cancer anyway (independently of radiation exposure),
and the radiation exposure may induce 1 additional cancer
(Figure 3). These estimates have a considerable margin of uncertainty,
with a 2 to 3 confidence interval of attributable risk estimates,18
which translates in the example above into an additional risk as
high as 1 in 30 or as low as 1 in 300.
Non-ionizing radiation is generally considered safe, but radiofre-
quency fields used in CMR are a possible (class IIb) carcinogen
according to the International Agency of Research on Cancer, and
the World Health Organization has urgently called an action in
order to evaluate adverse biological effects of clinical MR scanning,
Figure 2 Deterministic vs. stochastic effects (representative, not scaled). The stochastic risk is highest in children, higher in women than in men,
and reducedbyone-half in theelderly (.80yearsold). Modified fromoriginal dataofHealth Risks fromExposure toLowLevelsof IonizingRadiation:
BEIR VII, Phase 218, BEIR VII
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Highest (0.12) Breast Colon Lung Stomach Bone marrow
High (0.08) Ovaries Testes
Moderate (0.04) Thyroid Bladder Oesophagus Liver
Low (0.01) Bone Salivary glands Skin Brain
Very low (0.008) Heart Kidneys Pancreas Prostate (male) Uterus (female)
To calculate the effective dose (i.e. the biological risk corresponding to any given physical dose), the individual organ dose values are multiplied by the respective dimensionless tissue
weighing factor (taken from ICRP 200717). The higher this factor, the more radiosensitive the tissue, i.e. allowing a rough estimation of biological risk corresponding to any given
radiation dose. The sum of the tissue weighing factors is unity so that a uniform dose distribution in the whole body gives an effective dose numerically equal to the radiation-weighted
dose in each organ and tissue of the body.
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which is capable of producing detectable damage to human lympho-
cyte DNA integrity.24
Nuclear medicine: doses and risks
In the USA, nuclear cardiology accounts for .50% of all nuclear
medicine procedures and 85% of the entire cumulative ED due
to nuclear medicine, which accounted for 26% of the overall
medical exposure of patients in 2006.2 Table 3 summarizes the ED
for commonly performed studies.25,26,27 A number of strategies
can be used to minimize dose in cardiac nuclear imaging, such as
the useof 99mTc (technetium) sestamibi or tetrofosmin agents as pre-
ferred radiopharmaceuticals in single-photon emission computed
tomography (SPECT) and the use in patients with low pre-test prob-
ability of disease of stress-first/stress-only protocols.28 Radiation ex-
posure can be decreased by 75% using a protocol whereby stress
imaging is performed first (‘stress first’), with rest images eliminated
in patients with normal stress images (‘stress only’)—but in current
practice in the USA, it is seldom used due to gaps in practitioners’
knowledge pertaining to radiation safety.7 This same knowledge
gap leads to the 15% rate of dual radioisotope testing, which is
unacceptably high due to high ED involved (30 mSv). The new
SPECT detectors with cadmium zinc telluride technology can be
used to considerably decrease the ED and acquisition time for myo-
cardial perfusion SPECT with preserved image quality.7,26 A strategic
target of the nuclear cardiology community is that for the population
of patients referred for SPECT or positron-emission tomography
(PET) myocardial perfusion imaging, on average a total radiation
exposure of ,9 mSv can be achieved in 50% of studies by 2014.29
Computed tomography: doses
and risks
Use of computed tomography (CT) for diagnostic evaluation has
increased dramatically over the last two decades, from approximately
3 million in 1980 to nearly 70 million in 2007 in the USA, but the dose
per examination showed a clear downward trend, with a reduction of
three quarters of radiation dose in the last decade through increasing
use of dose-saving measures and evolving scanner technology.30
The ED of a calcium score study is substantially less (2–3 mSv)
than a coronary CT study (Table 3). The patient dose as expressed
by dose-length product can be converted into mSv (ED) with appro-
priate conversion factors, specific for the type of examination (chest
vs. coronary artery)31,32 (Table 4).
Recent emphasis on radiation exposure due to CT scanning has
engendered a competitive effort on the part of manufacturers to
reduce the dose while still providing images with sufficient diagnostic
quality. As a result, if the heart rate is sufficiently slow and regular,
cardiac CT angiography with a gated acquisition of a single frame
in end-diastole can now be performed producing high-quality diag-




Among adult cardiology patients, fluoroscopically guided diagnosis
and interventionaccount for12% of all radiological examinations per-
formed, and 48% of their total collective dose.20 There are estab-
lished correlation factors between ED and dose-area product
(DAP) or kerma-area product (KAP) values displayed by the equip-
ment as to indicating total energy imparted to the patient for
a given IC procedure. The wide range of EDs corresponding to
common examinations is reported in Table 3.33–36 As a general
rule, ED can be estimated approximately as follows: ED (mSv) ¼
DAP (Gy × cm2) × 0.2 (mSv/Gy cm2).37 The conversion factor
(from DAP to mSv) is age-specific,38 and increases with decreasing
age (Table 4). Consequently, DAP quantity represents a relevant dos-
imetry index, the value of which should be optimized against the
diagnostic reference level, which varies for each procedure and can
be used as a tool to comply with the ALARA (As Low As Reasonable
Achievable) principle.
Specific estimations of patient radiation dose for typical
EP procedures are listed in Table 3.39 The introduction of non-
radiology-based methods of cardiac mapping and the use of
co-registration of CT or CMR images of the target structures
(for instance, the left atrium) have the potential to drastically
reduce these doses.
Protection of personnel
The protection of doctors is just as important as protection of
patients. With conventional radiology and CT, occupational radi-
ation exposure is minimal since the staff leaves the room during
the procedure. In nuclear cardiology, professional exposure can
be as high as 2–5 mSv per year, although more frequently it
Figure3 The dose–effect relationship betweenradiation expos-
ure and cancer risk over background levels. The solid line indicates
the epidemiological evidence, which is conclusive for doses
.50–100 mSv. The dashed line indicates the dose range with in-
conclusive evidence. Below 50 mSv, the currently accepted linear
no-threshold model (continuous line) is based on the assumption
that the dose level (x-axis) is directly proportional to the cancer
risk (y-axis). In the supra-linear model, the risk is higher for any
givendose. In the hormetic model, lowdoses might evenhave a pro-
tective effect. Modified from original data of Health Risks from
Exposure to Low Levels of Ionizing Radiation: BEIR VII, Phase 218,
BEIR VII.
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remains ,1 mSv. Most experienced (and most exposed) interven-
tional cardiologists and electrophysiologists have an exposure per
annum of 5 mSv, two to three times higher than diagnostic radi-
ologists, with a typical cumulative lifetime attributable risk on the
order of magnitude of 1 cancer (fatal and non-fatal) per 100
exposed subjects.40 Operator dose per procedure correlates
somewhat with the patient dose, but may be typically 1000 times
lower depending upon the shielding employed (one unit of inci-
dence scatter dose for the operator when 1000 units of incident
dose are given to the patient).41 However, adequate radiation
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CXR (PA) 0.02 1 2–3 days Mettler et al.25
Invasive fluoroscopy
Diagnostic coronary angiography 7 (2–16) 350 2.9 Mettler et al.25
PCI 15 (7–57) 750 6.3 Mettler et al.25
Thoracic angiography (pulmonary or aorta) 5 (4–9) 250 2.1 Mettler et al.25
Abdominal angiography or aortography 12 (4–48) 600 5.0 Mettler et al.25
Pelvic vein embolization 60 (44–78) 3000 25.0 Mettler et al.25
TIPS placement 70 (20–180) 3500 29.3 Mettler et al.25
Aortic valvuloplasty 39 1950 16.2 Signorotto et al.33
Dilation chronic coronary occlusion 81 (17–194) 4050 33.7 Suzuki et al.34
ETAAAR procedure 76–119 3800–5950 31.6–49.5 Panuccio et al.35
Renal angioplasty 54 2700 22.5 Rehani et al.37
Iliac angioplasty 58 2900 24.1 Rehani et al.37
Paediatric Diagnostic cardiac catheterization 6.0 (0.6–23.2) Age-dependent 2.5 Bacher et al.36
Closure of ASD 2.8 (1.8–7.4) Age-dependent 1.1 Bacher et al.36
Patent ductus arteriosus occlusion 7.6 (2.1–37) Age-dependent 3.2 Bacher et al.36
Balloon valvuloplasty 8.1 (2.9–20) Age-dependent 3.3 Bacher et al.36
Adult Cardiac electrophysiology
Diagnostic EP studies 3.2 (1.3–23.9) 160 1.2 Heidbuchel et al.39
Ablation procedure: 15.2 (1.6–59.6) 760 5.7 Heidbuchel et al.39
AF 16.6 (6.6–59.2) 830 6.9 Heidbuchel et al.39
AT-AVNRT-AVRT 4.4 (1.6–25) 220 1.8 Heidbuchel et al.39
VT 12.5 (3 to ≥45) 625 5.2 Heidbuchel et al.39
Regular PM or ICD implant 4 (1.4–17) 200 1.6 Heidbuchel et al.39
CRT implant 22 (2.2–95) 1100 9.1 Heidbuchel et al.39
CT
64-slice coronary CTA 15 (3–32) 750 (150–1600) 6.25 Mettler et al.25
Calcium score 3 (1–12) 150 1.25 Mettler et al.25
Nuclear cardiology
PET F-18 FDG rest (400 MBq, viability) 8 400 3.3 ARSAC26
PET Rubidium-82 stress–rest (3700 MBq) 4.6 230 1.9 Gaemperli et al.27
PET N-13 ammonia stress–rest (1100 MBq) 2.4 120 1 Gaemperli et al.27
PET 15O-H2O stress–rest (2200 MBq) 2.5 125 1.04 Gaemperli et al.
27
99mTc-labelled erythrocytes (1110 MBq, cardiac function) 7.8 390 3.25 Gaemperli et al.27
SPECT-201Tl stress/redistr. (130 MBq, single injection) 22 1100 91.6 Gaemperli et al.27
201Thallium stress/rest reinj. (185 MBq, double injection) 40.7 2035 16.9 Mettler et al.25
99mTc -Sestamibi (1100 MBq, 1 day) stress–rest 9.4 470 3.9 Mettler et al.25
99mTc -Tetrofosmin (1500 MBq, 1 day) stress–rest 11.4 570 4.7 Mettler et al.25
Lung scintigraphy
99mTc -MAA (185 MBq, lung perfusion) 2 100 0.8 Mettler et al.25
133Xenon (400 MBq, lung ventilation) 0.4 20 0.2 ARSAC26
AF, atrial fibrillation; AT, atrial tachycardia; ASD, atrial septal defect; AVRT, atrio-ventricular reciprocal tachycardia; CXRs: chest X-rays; CRT, cardiac resynchronization therapy;
ETAAAR, endovascular thoraco abdominal aortic aneurysm repair; FDG, fluorodeoxyglucose; MAA, macroaggregated albumin; PCI, percutaneous coronary intervention; CT,
computed tomography; PET, positron-emission tomography; SPECT, single-photon emission computed tomography.
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protection training and diligent protection can reduce the radiation
exposure by 90%.42
Cardiac imaging in paediatric
cardiology
For any given radiological ED, the risk for some organs, including the
brain, is three to four times higher in children than in adults.17,18
Children are at substantially higher risk than adults because they
have more rapidly dividing cells and a greater life expectancy, allowing
the clinical manifestation of radiogenic cancer with long latency
periods of decades. Thus, an infant or a child patient has a longer life-
time risk for developing radiation-induced cancers than adult
patients. At the age of 15–20 years, grown-up congenital heart
disease patients have already cumulated an ED exposure corre-
sponding to 20–40 mSv, with an estimated lifetime attributable
extra-risk of cancer of 1 in 10 to 1 in 100.43 Among paediatric cardi-
ology patients with congenital heart disease, fluoroscopically guided
diagnosis and interventions account for 3.5% of all radiological exam-
inations performed and 84% of their total collective dose.43 In the
USA, this issue of radiological responsibility was addressed with
the Image Gently, Step Lightly Campaign, especially focused on the
risks of unnecessary and excessive medical radiation exposure
from interventional radiology administered to paediatric patients.44
Typical EDs for common paediatric examinations are reported in
Table 3. In paediatric catheterization, the conversion factor from
DAP to mSv (mSv ¼ DAP × 0.20 in adult cardiology patients) is
higher (Table 4).
Cardiac imaging in women
and in pregnancy
For any given radiation exposure, the cancer risk is higher in females
(by38%) than in males at all ages. In women in childbearing age, the
dose to gonads should also be known45 and minimized (Table 5).
Knowledge of foetal and mother dosimetry may affect the choice
of testing in the pregnant patient. This is especially relevant in
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Table 4 Conversion factors: from jargon to effective dose
CT Conversion factor Reference
DLP (for chest) mSv ¼ DLP (mGy × cm) × 0.021 Christner et al.31
DLP (for coronary arteries) mSv ¼ DLP (mGy × cm) × 0.030 Geleijns et al.32
Radiology
KAP in adults mSv ¼ KAP (Gy cm2) × 0.2 Rehani37
KAP in 15 year olds mSv ¼ KAP (Gy cm2) × 0.4 Karambatsakidou et al.38
KAP in 5 year olds mSv ¼ KAP (Gy cm2) × 1.0 Karambatsakidou et al.38
KAP in ,1 year olds mSv ¼ KAP (Gy cm2) × 1.9 Karambatsakidou et al.38
KAP in newborns mSv ¼ KAP (Gy cm2) × 3.7 Karambatsakidou et al.38
Nuclear cardiology
SPECT 99mTc–sestamibi (rest) mSv ¼ MBq × 0.0092 Einstein et al.28
SPECT 99mTc–sestamibi (stress) mSv ¼ MBq × 0.0078 Einstein et al.28
SPECT 99mTc–tetrofosmin (rest) mSv ¼ MBq × 0.0073 Einstein et al.28
SPECT 99mTc–tetrofosmin (stress) mSv ¼ MBq × 0.0065 Einstein et al.28
SPECT-201Tl (stress-redistribution) mSv ¼ MBq × 0.22 Gaemperli et al.27
PET 13N-ammonia (stress–rest) mSv ¼ MBq × 0.0022 Gaemperli et al.27
PET 15O-H2O (stress–rest) mSv ¼ MBq × 0.0011 Gaemperli et al.27
PET 82Rb (stress–rest) mSv ¼ MBq × 0.0036 Gaemperli et al.27
PET 18F-FDG (rest) mSv ¼ MBq × 0.0189 Gaemperli et al.27
CT, computed tomography; KAP, kerma-area product; DLP, dose-length product; PET, positron-emission tomography; SPECT, single-photon emission computed tomography.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Gonad dose for diagnostic examinations
Diagnostic exposure Gonad dose (mSv)
Abdominal X-ray 0.7
Pelvis and hip X-ray 4
Lower GI series (M/F) 90/36
CT chest 0.02
CT abdomen 3.7
CT pelvis and hips 20
Lower limb angiography 5.1
Body scintigraphy 3.0
Nuclear stress test (M/F) 2/13
PET scan 4
CT, computed tomography; PET, positron-emission tomography.
Adapted from Latini et al.45
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pulmonary embolism, which is the leading cause of maternal mor-
tality in the developed world. Also on the basis of radioprotection
considerations, strong recommendations were made by the Ameri-
can Thoracic Society for three specific scenarios: performance of
CXR as the first radiation-associated procedure; use of lung scintig-
raphy (with a breast dose to mother 20 to 100 times lower than CT
pulmonary angiography, with only slightly higher foetal dose) as the
preferred test in the setting of a normal CXR; and performance of
CT pulmonary angiography (whole-body maternal ED ¼ 4–
18 mSv) rather than digital subtraction angiography (7–28 mSv)
in a pregnant woman with a non-diagnostic ventilation–perfusion
result.46
For professionally exposed workers, pregnant workers can
continue to work with radiation limits ,1 mSv (foetal dose during
full pregnancy) in many European countries, with the recommenda-
tion to communicate one’s pregnancy to the competent hospital
service. Allowed doses are higher in the USA, up to ,5 mSv
(measured by a waist dosimeter) for the entire pregnancy.47
Informed consent form
In radiological informed consent, the communication of doses and
risks is often based on a highly specialized technical language, often
difficult to understand even for practitioners and radiologists. As a
result, both patients and doctors often are unaware of what they
are doing, in terms of doses and radiation risks.6,7 The informed
consent form should spell out, in tabular form and possibly with a
figure, the specific reference dose.48 After the examination, the actu-
ally delivered dose should be stored in the patient’s and laboratory’s
records. The jargon information should be translated into mSv,
equivalent number of chest radiographs, and equivalent periods of
natural background radiation (Table 6). After the procedure, the
patient should be provided with dose information if he/she asks
and this has become a requirement enforced by law in many coun-
tries. Effective dose has the advantage that it is not modality-specific
and can be cumulated between different imaging modalities over
time. This simple consent process will gently force the doctor to
learn what he/she already should know, enabling him/her to make
more responsible choices.49
Take-homemessage
All other considerations being equal, it is not recommended to
perform tests involving ionizing radiation when the desired informa-
tion can be obtained with a non-ionizing test with comparable accur-
acy. If you perform a test that utilizes ionizing radiation, choose the
one with the lowest dose and be aware of the many factors modulat-
ing dose. The actual delivered dose should always be recorded and
included in patients’ records. Because of the numerous sources of
variability, there is no clear threshold between acceptable and un-
acceptable exposure for any given examination, but the dose that is
not even considered is certainly unacceptable.
X-rays and g-rays used in radiology and nuclear medicine are
proven (class 1) carcinogens, and cardiologists should make every
effort to give ‘the right imaging exam, with the right dose, to the
right patient’.50 The priority given to radioprotection in every cardi-
ology department is an effective strategy for primary prevention of
cancer, a strong indicator of the quality of the cardiology division,
and the most effective shielding to enhance the safety of patients,
doctors, and staff. A smart cardiologist cannot be afraid of the essen-
tial and often life-saving use of medical radiation, but must be very
afraid of radiation unawareness.
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